Batimastat: Antineoplastic matrix metalloproteinase inhibitor

Drugs of the Future

Volumn 21, Issue 12, 1996, Pages 1215-1220

  Ngo, J ^a   Graul, A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BATIMASTAT; BB 374; COLLAGENASE; MATRIX METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; STROMELYSIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ASCITES TUMOR; BREAST CANCER; CELL LINE; CELL PROLIFERATION; COLON CANCER; DRUG BLOOD LEVEL; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAPLEURAL DRUG ADMINISTRATION; METASTASIS; NONHUMAN; PLEURA EFFUSION; PTERYGIUM; SHORT SURVEY;

EID: 0030513245     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1996.021.12.384881     Document Type: Article

References (40)

1. Campion, C., Davidson, A.H., Dickens, J.P., Crimmin, M.J. (British Bio-technology, Ltd.). Hydroxamic acid based collagenase inhibitors. US 5240958, US 5310763, WO 9005719.
2. Matrisian, L.M. The matrix degrading metalloproteinases. Bioessays 1992, 14: 455-62.
3. Kleiner, D.E., Stetler-Stevenson, W.G. Structural biochemistry and activation of matrix metalloproteinases. Curr Opin Cell Biol 1993, 5: 891-7.
4. Cottam, D.W., Rees, R.C. Regulation of matrix metalloproteinases: Their role in tumor invasion and metastasis. Int J Oncol 1993, 2: 861-72.
5. Daidone, M.G., Silvestrini, R., D'Errico, A.D., Di Fronzo, G., Benini, E., Mancini, A.M., Garbisa, S., Liotta, L.A., Grigioni, W.F. Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. Int J Cancer 1991, 48: 529-32.
6. Brown, P.D., Bloxidge, R.E., Anderson, E., Howell, A. Expression of activated gelatinase in human invasive breast cancer. Clin Exp Metastasis 1993, 11: 183-9.
7. Davies, B., Miles, D.W., Happerfield, M.L.C., Naylor, M.S., Bobrow, L.G., Rubens, R.D., Balkwill, F.R. Activity of type IV colla-genases in benign and malignant breast disease. Brit J Cancer 1993, 67: 1126-31.
8. Zucker, S., Lysik, R.M., Zarrabi, M.H., Moll, U. Mr 92.000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 1993, 53: 140-6.
9. DeClerck, Y.A., Perez, N., Shimada, H., Boone, T.C., Langley, K.E., Taylor, S.M. Inhibition of invasion and metastasis in cells transfectd with an inhibitor of metalloproteinases. Cancer Res 1992, 52: 701-8.
10. Khokha, R., Zimmer, M.J., Graham, C.H., Lala, P.K., Water-house, P. Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells. J Natl Cancer Inst 1992, 84: 1017-22.
11. Birkedal-Hansen, H., Moore, W.G.I., Bodden, M.K., Windsor, L.J., Birkedal-Hansen, B., DeCarlo, A., Engler, J.A. Matrix metallo-proteinases: A review. Crit Rev Oral Biol Med 1993, 4: 197-250.
12. Beckett, R.P., Crimmin, M.J., Galloway, W.A. Matrix metalloproteinase inhibitors in the treatment of rheumatoid arthritis and cancer. 205th ACS Natl Meet (March 28-April 2, Denver) 1993, Abst MEDI 147.
13. Sledge, G.W. Jr., Qulali, M., Goulet, R., Bone, E.A., Fife, R. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 1995, 87: 1546-50.
14. Brown, P.D., Crimmin, M.J., Drummond, A.M., Davidson, A.M., Galloway, A., Millar, A.W. Matrix metalloproteinase inhibitors: A novel class of anticancer agents. 5th Int Cong Anti-Cancer Chemother (Jan 31-Feb 3, Paris) 1995, Abst O 516.
15. Taraboletti, G., Garofalo, A., Belotti, D., Drudis, T., Borsotti, P., Scanziani, E., Brown, P.D., Giavazzi, R. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995, 87: 293-8.
16. Sledge, G., Qulali, M., Bone, E.A., Fife, R. Combination matrix metalloproteinase (MMP) inhibition in an athymic mouse xenograft model of human breast cancer (BC) metastasis. Proc Amer Assoc Cancer Res 1996, 37: Abst 639.
17. Jerian, S.M., Stetler-Stevenson, W.G. BB-94 is active against human breast carcinoma in an orthotopic model. Proc Amer Assoc Cancer Res 1994, 35: Abst 2389.
18. Eccles, S.A., Box, G.M., Court, W.J., Bone, E.A., Thomas, W., Brown, P.D. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 1996, 56: 2815-22.
19. Davies, B., Brown, P.D., East, N., Crimmin, M.J., Balkwill, F.R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993, 53: 2087-91.
20. Low, J. A. .Johnson, M.D., Bone, E.A., Dickson, R.B. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin Cancer Res 1996, 2: 1207-14.
21. Eccles, S., Box, G., Court, W., Bone, E., Brown, P. Control of lymphatic and blood-borne metastasis of a rat breast carcinoma by the matrix metalloproteinase inhibitor, batimastat. Proc Amer Assoc Cancer Res 1996, 37: Abst 505.
22. Giavazzi, R., Garofalo, A., Lucchini, V., Brown, P., Bone, E., Mangioni, C., Nicoletti, M.I. Enhancement of cisplatin antitumor activity by batimastat in human ovarian carcinoma xenografts. 9th NCI-EORTC Symp New Drugs Cancer Ther (March 12-15, Amsterdam) 1996, Abst 127.
23. Wang, X., Fu, X., Brown, P.D., Crimmin, M.J., Hoffman, R.M. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994, 54: 4726-8.
24. Nicoletti, M.I., Garofalo, A., Lucchini, V., Brown, P., Rossi, R., Giavazzi, R. Batimastat potentiates cisplatin activity on human ovarian carcinoma xenografts. Eur J Cancer 1996, 32A(Suppl. 1): Abst 28 O.
25. Giavazzi, R., Garofalo, A., Valoti, G., Valla, R., Rossi, R. Batimastat (BB-94) in combination with cisplatin inhibits human ovarian carcinoma xenografts. Proc Amer Assoc Cancer Res 1996, 37: Abst 629.
26. Knox, J.D., Bowden, G.T., Breton, L., Nagle, R.B. The inhibition of prostate tumor cell invasion by batimastat (BB-94) in a diaphragm invasion model. Proc Amer Assoc Cancer Res 1996, 37: Abst 598.
27. Burke, F., East, N., Balkwill, F.R. Sequential cytokine and matrix metalloprotease inhibitor therapy in a model of human ovarian cancer. Proc Amer Assoc Cancer Res 1996, 37: Abst 651.
28. Watson, S.A., Morris, T.M., Robinson, G., Crimmin, M.J., Brown, P.D., Hardcastle, J.D. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995, 55: 3629-33.
29. Watson, S.A., Morris, T.M., Parsons, S.L., Steele, R.J.C., Brown, P.D. Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model. Brit J Cancer 1996, 74: 1354-8.
30. Wang, X., Fu, X., Brown, P.D., Crimmin, M.J., Hoffman, R.M. Metalloproteinase inhibitor BB 94 is effective against metastatic colon cancer in a patient-like orthotopic mouse model (Meta-Mouse). Proc Amer Assoc Cancer Res 1994, 35: Abst 2801.
31. Zempo, N., Koyama, N., Kenagy, R.D., Lea, H.J., Clowes, A.W. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metallo-proteinase inhibitor. Arterioscler Thromb Vasc Biol 1996, 16: 28-33.
32. Botos, I., Scapozza, L., Zhang, D., Liotta, L.A., Meyer, E.F. Batimastat, a potent matrix metalloproteinase inhibitor, exhibits an unexpected mode of binding. Proc Natl Acad Sci USA 1996, 93: 2749-54.
33. Kinoshita, T., Sato, H., Takino, T., Itoh, M., Akizawa, T., Seiki, M. Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase A by a recombinant membrane-type 1 matrix metallo-proteinase. Cancer Res 1996, 56: 2535-8.
34. Wojtowicz, S., Ness, E., Dickson, R., Low, J., Barter, J., Sale, M., McCann, P., Hawkins, M. Pharmacokinetics (PK) of batimastat (BB-94), a novel matrix metalloproteinase inhibitor (MMPI) admin-istered intraperitoneally. Proc Amer Soc Clin Oncol 1995, 14: Abst 1536.
35. Beattie, G.J., Young, H.A., Smyth, J.F. Phase I study of intraperitoneal metallo-proteinase inhibitor BB94 in patients with malignant ascites. Ann Oncol 1994, 5(Suppl. 5): Abst 015.
36. O'Byrne, K.J., Macaulay, V.M., Long, L., Propper, D., Bray-brooke, J., Gleeson, F., Ganesan, T.S., Harris, A.L, Talbot, D.C. Phase I study of matrix metalloproteinase (MMP) inhibitor batimastat (BB94) in patients (pts) with malignant pleural effusions. 9th NCI-EORTC Symp New Drugs Cancer Ther (March 12-15, Amsterdam) 1996, Abst 254.
37. Wojtowicz-Praga, S., Low, J., Marshall, J. et al. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs 1996, 14: 193-202.
38. Parsons, S.L., Watson, S.A., Amar, S.S., Steele, R.J.C. Phase I/II trial of a matrix metalloproteinase inhibitor in patients with malignant ascites. Gastroenterology 1996, 110(4, Suppl.): A575.
39. InSite Vision announces restructuring. InSite Vision Inc. Press Release 1995, November 2.
40. British Biotech plc results for the three months ended 31st October 1996. British Biotech plc Press Release 1996, November 27.